Longboard Pharmaceuticals has announced the first sites for the  DEEp OCEAN study, a trial in the DEEp Program to evaluate bexicaserin (LP352) as a potential treatment for those living with developmental and epileptic encephalopathies! This study will evaluate bexicaserin for the treatment of seizures in DEEs for ages 2 years and older. In July of this year, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for bexicaserin for treating seizures associated with Developmental and Epileptic Encephalopathies (DEEs). This was the first of its kind designation. This is important to our community, because CDKL5 deficiency disorder (CDD) is considered a DEE, meaning CDD patients may qualify for this clinical trial.

You can learn more by reading this letter to the community, the formal press release, and visiting the official website DEEpDEEStudy.com. We appreciate Longboard’s diligence in continually working to inform and update the community.

Here is a list of the first three activated sites:

NW FL Clinical Research Group, LLC
400 Gulf Breeze Pkwy, Ste 203
Gulf Breeze, Florida 32561
Research Institute of Orlando LLC
2881 Delaney Ave Ste. C
Orlando, Florida 32806
Institute of Neurology and Neurosurgery at Saint Barnabas, LLC
200 S. Orange Ave. Ste 165
Livingston, New Jersey 07039